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Background: To clarify the significant clinicopathological and postdosimetric parameters to predict PSA bounce in
patients who underwent low-dose-rate brachytherapy (LDR-brachytherapy) for prostate cancer.
Methods: We studied 200 consecutive patients who received LDR-brachytherapy between July 2004 and
November 2008. Of them, 137 patients did not receive neoadjuvant or adjuvant androgen deprivation therapy. One
hundred and forty-two patients were treated with LDR-brachytherapy alone, and 58 were treated with LDR-
brachytherapy in combination with external beam radiation therapy. The cut-off value of PSA bounce was 0.1 ng/
mL. The incidence, time, height, and duration of PSA bounce were investigated. Clinicopathological and
postdosimetric parameters were evaluated to elucidate independent factors to predict PSA bounce in hormone-
naïve patients who underwent LDR-brachytherapy alone.
Results: Fifty patients (25%) showed PSA bounce and 10 patients (5%) showed PSA failure. The median time,
height, and duration of PSA bounce were 17 months, 0.29 ng/mL, and 7.0 months, respectively. In 103 hormone-
naïve patients treated with LDR-brachytherapy alone, and univariate Cox proportional regression hazard model
indicated that age and minimal percentage of the dose received by 30% and 90% of the urethra were independent
predictors of PSA bounce. With a multivariate Cox proportional regression hazard model, minimal percentage of the
dose received by 90% of the urethra was the most significant parameter of PSA bounce.
Conclusions: Minimal percentage of the dose received by 90% of the urethra was the most significant predictor of
PSA bounce in hormone-naïve patients treated with LDR-brachytherapy alone.
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Table 1 Patients’ characteristics
Bounce (-) Bounce (+) p value
(n = 150) (n = 50)
Age (year)
mean, median (range) 69.2, 70.0 (55-80) 67.4, 68.5 (51-79) 0.132}
PSA at diagnosis (ng/mL)
mean, median (range) 9.1, 7.8 (3.1-32.1) 7.8, 6.7 (3.7-16.7) 0.029}
10 or less 106 41
10-20 37 9
greater than 20 7 0 0.156*
biopsy Gleason score
6 or less 91 37
7 53 11





T2c 5 1 0.904*
neo-Adjuvant/ Adjuvant
none 102 35
neo-Ad (+) 40 15
Ad (+) 4 0
neo-Ad (+), Ad (+) 4 0 0.417*
Combined EBRT
yes 49 9
no 101 41 0.050*
biochemical recurrence
yes 10 0
no 140 50 0.069*
Number of PSA measurement
mean, median (range) 8.5, 8.0 (5-15) 10.3, 10.5 (6-14) < 0.001}
Follow-up period (month)
mean, median (range) 36.7, 36.0 (18-64) 46.0, 47.0 (20-65) < 0.001}
*Chi-square test and }student t-test.
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Several investigators have reported PSA (prostate-spe-
cific antigen) bounce, a transient PSA elevation that is
frequently observed after low-dose-rate brachytherapy
(LDR-brachytherapy) [1-10]. Although the factors that
affect PSA fluctuation after LDR-brachytherapy are un-
clear, multiple factors including age, prostatitis due to
radiation or urinary tract infection, acute urinary reten-
tion, laboratory error, instrumentation, ejaculation, radi-
ation proctitis, and testosterone recovery after androgen
deprivation therapy (ADT) are currently considered as
etiologies of PSA bounce. Most importantly, it is difficult
to differentiate between PSA bounce and biochemical
failure, and this situation produces a dilemma for
patients and physicians to determine whether the treat-
ment has failed or not. Several cut-off values of PSA,
such as 0.1, 0.2, and 0.4 ng/mL, have been used to define
PSA bounce. Seventeen to 62% of patients who under-
went LDR-brachytherapy showed a PSA bounce during
the first 3 years after LDR-brachytherapy [1-10]. The in-
cidence of PSA bounce in Japanese patients is reportedly
similar to that in American patients [8,9].
We investigated PSA bounce rates after LDR-
brachytherapy to elucidate independent predictors of
PSA bounce in our series of patients.
Methods
Two hundred patients who were clinically diagnosed
with localized prostate cancer (cT1c-2cN0M0) and
underwent LDR-brachytherapy between July 2004 and
November 2008 and a minimum follow-up of 18 months
were enrolled in this prospective study. The patients’
characteristics are shown in Table 1. The median age,
PSA value at diagnosis, and follow-up period were
70 years (range: 51–80), 7.6 ng/mL (range: 3.1-32.1), and
38 months (range: 18–65), respectively. One pathologist
(NK) with expertise in prostate cancer diagnosis
reviewed the Gleason score of all biopsy specimens cen-
trally. The PSA values (PSA; ST AIA-PACK PSA II) were
measured at 1, 3, and 6 months after LDR-brachyther-
apy, and then every 6 months.
The institutional review board of Nara Medical Uni-
versity approved this study, and informed consent was
obtained from all patients after explaining the aim and
methods of this study.
Treatment
Among the 200 patients, 137 did not receive neoadju-
vant or adjuvant androgen deprivation therapy (ADT),
and 4 received both neoadjuvant and adjuvant ADT.
The median period of neoadjuvant ADT was 6.0 months
(range: 1 to 54 months), and the scheduled period of ad-
juvant ADT was 2 years. Of the remaining patients, 55
received only neoadjuvant ADT and 4 received onlyadjuvant ADT. One hundred and forty-two patients
were treated with LDR-brachytherapy alone and 58
patients were treated with LDR-brachytherapy in com-
bination with external beam radiation therapy (EBRT)
(Table 1).
From July 2004 to April 2007, LDR-brachytherapy
alone was performed at the prescribed dose of 145 Gy in
93 patients, and after May 2007 it was performed at the
prescribed dose of 160 Gy in 49 patients. The prescribed
dose was 110 Gy for the patients who received LDR-
brachytherapy in combination with EBRT. The target
portion of EBRT was determined one month after LDR-
brachytherapy, and the patients received 45 Gy (in 25
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technique via 6–10 MV photon energy. The clinical tar-
get volume included both the whole prostate and one
third of the proximal seminal vesicle.
From July 2004 to April 2007, LDR-brachytherapy was
performed after preplanning by modified peripheral
loading techniques using Mick’s applicator [11]. From
May 2007 to October 2008, we introduced an intrao-
perative planning method, and thereafter used real-time
planning and peripheral loading.
Postdosimetric evaluation
The therapeutic planning and post-implant dosimetric
evaluation were performed using the planning system,
Interplant Version 3.3 (CMS, Inc., St. Louis, USA) from
July 2004 to October 2008, and thereafter Variseed 8.0
(Varian Medical Systems, Palo Alto, CA, USA).
Post-implant CT scanning and post-implant dosimetric
study was performed by one radio-oncologist (AI) at
1 month after LDR-brachytherapy. The dosimetric para-
meters analyzed in this study were minimal percentage
of the dose received by 90% of the prostate gland (%
D90), minimal dose (Gy) received by 90% of the prostate
gland (D90), percentage prostate volume receiving 100%
and 150% of the prescribed minimal peripheral dose
(V100/150), minimal percentage of the dose received by
30% and 90% of the urethra (%UD30 and%UD90), min-
imal dose (Gy) received by 30% and 90% of the urethra
(UD30 and UD90), and rectal volume (mL) receiving
100% of the prescribed dose (R100).
Statistic analysis
To elucidate independent factors to predict PSA bounce
in hormone-naïve patients who underwent LDR-
brachytherapy alone, prostate volume at implantation,
prostate volume at postdosimetry,%D90, D90, V100,
V150, R100,%UD90, UD90,%UD30, and biologically ef-
fective dose (BED) were evaluated. The BED was calcu-
lated to evaluate an independent factor to predict PSA
bounce, and an α/β ratio of 2 was used [12].
In this study, PSA bounce was defined as an elevation
in the PSA value of 0.1 ng/mL or more compared to the
previous lowest value (excluding the 1 month PSA
value), followed by a decline to a level at or below the
pre-bounce value. We used Phoenix definition
(nadir + 2 ng/mL) as the definition of PSA failure [13].
Estimated PSA bounce-free rate was calculated by the
Kaplan-Meier method. Cox proportional hazards model
was used to determine predictive parameters of PSA
bounce both in univariate and multivariate analysis
(backward stepwise selection method). To analyze the
differences in categorical parameters, the chi-square test
was employed. Student’s t-test was used to evaluate the
differences in continuous variables. ANOVA byBonferroni’s procedure and Dunnett’s procedure were
applied to intergroup comparisons of the incidence of
PSA elevation of ≥0.1 ng/mL, as well as the incidence,
time, height, and duration of PSA bounce among the 4
groups treated with monotherapy with or without
neoadjuvant ADT and combination therapy with or
without neoadjuvant ADT. All statistical analyses were
performed using PASW Statistics 17.0 (SPSS Inc., Chi-
cago, IL, USA). All p values below 0.05 were considered
statistically significant.
Results
Of all patients, 92 (46%) showed PSA elevation of 0.1 ng/
mL or greater from a PSA nadir during the follow-up
period. The mean duration from LDR-brachytherapy to
the PSA elevation was 17.4 months (median: 17 months).
Of these 92 patients, 10 showed PSA failure and 50
showed PSA bounce (54%). The mean time to PSA
bounce was 16.4 months (median: 17 months). The mean
height and duration of PSA bounce were 0.49 ng/mL (me-
dian: 0.29 ng/mL) and 9.8 months (median: 7.0 months),
respectively. The estimated 3-year PSA bounce-free rate
was 72.4%. The mean number of PSA measurements in
patients without PSA bounce was 8.5 (median: 8) while
that in patients with PSA bounce was 10.3 (median: 10.5).
PSA was more frequently measured in patients with PSA
bounce than in those without it (p< 0.001) (Table 1). Of
these 50 patients with PSA bounce, 8 (16%) showed a sec-
ond PSA bounce. The mean duration from LDR-
brachytherapy to the second PSA bounce was 29.3 months
(median: 29.5 months). The mean height and duration of
the second PSA bounce were 0.47 ng/mL (median:
0.18 ng/mL) and 6.8 months (median: 6.0 months),
respectively.
The mean PSA value at diagnosis was significantly
higher in patients without PSA bounce than in patients
with PSA bounce. The mean follow-up period and the
number of PSA measurements in patients without PSA
bounce were significantly shorter and smaller than those
in patients with PSA bounce. There was no significant
difference in the prostate volume at postdosimetry be-
tween patients with and without PSA bounce (Table 1).
Regarding postdosimetric parameters,%D90, V100,
V150, and R100 showed no significant differences be-
tween patients with and without PSA bounce, while
UD90 (%) and UD90 (Gy), showed a significantly higher
value in patients with PSA bounce. Patients without PSA
bounce showed a significantly higher BED (Table 2).
The incidence of PSA elevation of ≥0.1 ng/mL, the
incidence of PSA bounce, the mean time to PSA
bounce, the mean height of PSA bounce, and the esti-
mated 3-year PSA bounce-free rate of each treatment
group are summarized in Table 3. The incidence of
PSA elevation of >0.1 ng/mL was significantly higher
Table 2 Postdosimetric parameters (all patients: n = 200)
Bounce (-) (n=150) Bounce (+) (n=50) P value
(mean ± SD) (mean ± SD) (t-test)
Prostate volume at postdosimetry (mL) 27.3 ± 8.7 29.0 ± 8.9 0.233
%D90 (%) 110.6 ± 9.9 109.7 ± 9.1 0.577
D90 (Gy) 152.3 ± 24.5 153.3 ± 19.4 0.772
V100 (%) 93.7 ± 3.6 93.5 ± 3.6 0.700
V150 (%) 62.3 ± 10.4 62.1 ± 10.3 0.881
R100 (mL) 0.10 ± 0.19 0.08 ± 0.10 0.668
Urethral volume (mL) 0.53 ± 0.28 0.41 ± 0.23 0.004
%UD90 (%) 97.6 ± 12.8 101.8 ± 12.7 0.049
UD90 (Gy) 134.1 ± 24.5 142.5 ± 23.6 0.035
%UD30 (%) 140.2 ± 18.0 143.8 ± 22.3 0.256
Minimal urethral dose (Gy) 100.9 ± 21.6 111.3 ± 22.2 0.004
BED (Gy2) 188.5 ± 25.2 177.0 ± 23.2 0.005
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in the combination therapy without neoadjuvant ADT
group (ANOVA; p = 0.006), whereas the incidence of
PSA bounce showed no significant difference between
the groups. The mean height of PSA bounce in the
monotherapy without neoadjuvant ADT group was sig-
nificantly higher than that in the monotherapy with
neoadjuvant ADT group (ANOVA; p= 0.005), whereas
the time to PSA bounce and PSA bounce duration
showed no significant difference between the two
groups. The estimated 3-year bounce-free rate of the
monotherapy without neoadjuvant ADT, combination
therapy without neoadjuvant ADT, monotherapy with
neoadjuvant ADT, and combination therapy with
neoadjuvant ADT groups were 68.8%, 80.6%, 66.7%,
and 80.9%, respectively. Patients who underwent adju-
vant ADT (n = 8) showed no PSA bounce during the




PSA elevation rate of 0.1 ng/mL or greater 51 (50%)
Frequency of PSA bounce 29 (28%)
Time to bounce (mos) 17.4, 17, (5-36)
Mean, median, (range)
Height (ng/mL) 0.51, 0.34, (0.13-1.74) 0
Mean, median, (range)
Duration (mos) 9.1, 6.0, (3-36)
Mean, median, (range)
3-yr bounce free rate (%) 68.8differences in the estimated 3-year PSA bounce-free
rates among the 4 groups (log-rank test).
Subgroup analysis in hormone-naïve patients who
underwent LDR-brachytherapy alone
The mean %UD90, UD90 and %D30% in patients who
showed PSA bounce were significantly higher than
those in patients without PSA bounce (Table 4). A
univariate Cox proportional regression hazard model
showed that age, %UD30, and %UD90 were independ-
ent predictors of PSA bounce after LDR-brachyther-
apy. Finally, %UD90 was the most significant
parameter of PSA bounce in the multivariate Cox
proportional regression hazard model (Table 5).
Discussion
PSA bounce, which is frequently observed after LDR-
brachytherapy, is a curious phenomenon caused by anaive Neo-adjuvant ADT
Combined EBRT monotherapy Combined EBRT
(n=38) (n=34) (n=17)
25 (66%) 9 (27%) 6 (35%)
12 (32%) 3 (18%) 15 (18%)
14.8, 11.5 (5-35) 13.7, 8.5, (5-26) 18.3, 15, (14-26)
.48, 0.26, (0.12-1.85) 0.19, 0.16, (0.10-0.40) 0.90, 0.68, (0.16-1.87)
11.8, 11.5, (2-31) 6.0, 6.0, (3-9) 15.3, 17.0, (7-22)
80.6 66.7 80.9
Hormone naïve, monotherapy  (n=103)
Neo-adjuvant ADT,  monotherapy  (n=38)
Hormone naïve, combined with EBRT  (n=34)
Neo-adjuvant ADT, combined with EBRT  (n=17)
Adjuvant ADT (n=8)













Figure 1 PSA bounce (0.1 ng/mL)-free rate in all patients stratified by treatment procedure (neoadjuvant/ adjuvant ADT and
monotherapy/ combination with EBRT).
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are diagnosed with PSA bounce using several definitions
[1-10]. The median time to PSA bounce varied from
15 months to 26 months [1,2,4,6,7,9,10]. The median
height of PSA bounce was 0.4 ng/mL to 0.8 ng/mL
[1,2,4,6-9]. The median duration of PSA bounce was
6.8 months to 22.5 months [2,3,6,7]. In daily practice, doc-
tors and patients are annoyed when PSA elevation shows
biochemical recurrence or PSA bounce due to the com-
paratively high incidence and long duration of PSA







(mean ± SD) (mean ± SD) (t-test)
Age (year) 68.8 ± 6.1 66.1 ± 7.7 0.060
PV at postdosimetry (mL) 27.9 ± 8.0 30.8 ± 8.2 0.109
%D90 (%) 110.1 ± 10.4 112.1 ± 8.0 0.338
D90 (Gy) 167.6 ± 17.6 164.3 ± 12.5 0.360
V100 (%) 93.6 ± 3.8 94.4 ± 2.7 0.272
V150 (%) 62.7 ± 8.9 65.5 ± 8.8 0.163
R100 (mL) 0.10 ± 0.20 0.10 ± 0.10 0.936
Urethral volume (mL) 0.55 ± 0.26 0.42 ± 0.23 0.019
%UD90 (%) 95.6 ± 12.1 104.7 ± 11.3 0.001
UD90 (Gy) 145.3 ± 18.2 153.3 ± 16.2 0.041
%UD30 (%) 140.2 ± 16.1 151.5 ± 21.8 0.005
Minimal urethral dose (Gy) 107.5 ± 19.3 119.1 ± 16.6 0.006
BED (Gy2) 177.5 ± 19.7 173.7 ± 13.9 0.354bounce, the median time to PSA bounce, the median
height of PSA bounce, and the median duration of PSA
bounce were 25%, 17 months, 0.29 ng/mL, and
7.0 months, respectively. The median height in our series
was lower than that in previous studies. Presumably, it
was caused by the definition of PSA bounce (cut-off value
of 0.1 ng/mL).
In the subgroup analysis, the incidence of PSA ele-
vation of ≥0.1 ng/mL was significantly higher in the
monotherapy with neoadjuvant ADT group than the
combination therapy without neoadjuvant ADT
(p= 0.006) group. However, the incidence of PSA
bounce was not significantly different in these four
groups. This result was comparable to that of previ-
ous reports [5,6,10]. Moreover, the estimated 3-year
bounce-free rates in these four groups showed no sig-
nificant differences in this study.
The present study showed that %UD90, UD90, and
BED were significantly different between patients with
PSA bounce and those without PSA bounce, whereas
age and prostate volume showed no significant differ-
ence among all patients. To avoid the influence of
neoadjuvat/adjuvant ADT and EBRT, we evaluated theTable 5 Univariate and multivariate analyses to predict
PSA bounce (Cox proportional regression hazard model)
Univariate Multivariate p - value 95% C.I.
p - value Hazard ratio
Age 0.044
%UD90(%) 0.004 1.037 0.007 1.010-1.064
%UD30 (%) 0.011
C.I confidence interval.
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ted with LDR-brachytherapy alone without neoadju-
vant/adjuvant ADT. In this group, %UD90, UD90 and
%UD30 showed a significant difference between
patients with PSA bounce and those without PSA
bounce, while age showed a marginal difference
(p= 0.06). Previous studies have reported that age,
D90, isotope, and prostate volume were the significant
predictive factors of PSA bounce [3-9]. On the other
hand, age, %UD90 and %UD30 were significant pre-
dictive parameters of PSA bounce by univariate ana-
lysis using a Cox proportional regression hazard
model in this study. Multivariate analysis indicated %
UD90 as predictive parameters. The pathological rea-
son why %UD90 affects the incidence of PSA bounce
is unknown. It is most probable that a higher dose to
the urethra causes a higher incidence of radiation-
induced urethritis and prostatitis.
Various factors including age, radiation-induced procti-
tis, prostatitis (radiation-induced or infection), ejaculation,
laboratory error, urinary retention, testosterone recovery
after ADT, and instrumentation, are considered as etiolo-
gies of PSA bounce. Assessment strongly suggests that
sexual activity, inflammatory stimulation and androgen
manipulation are associated with PSA bounce. It is neces-
sary to investigate the correlation between PSA bounce
and the data of urine analysis, urodynamics study, and
serum androgen level in the future.
Our present study has some limitations such as a
small number of patients and a short follow-up
period. Indeed, there were only 50 patients who
showed PSA bounce out of the 82 patients with PSA
elevation of ≥ 0.1 ng/mL after LDR-brachytherapy
without PSA failure. The other 32 patients with PSA
elevation did not reach the PSA nadir level during
the follow-up period. Longer follow-up is necessary to
confirm PSA bounce in this patient group. The differ-
ence in the prescribed monotherapy dose (145 Gy vs.
160 Gy) may also influence the incidence of PSA
bounce. In this study, we did not evaluate this matter
because the follow-up period of the patients who
received a prescribed dose of 160 Gy was significantly
shorter than that of the patients who received 145 Gy
(data not shown). The definition of PSA bounce is
also controversial. In this study, we adopted a cut-off
value of 0.1 ng/mL. The results of studies with a
longer follow-up period and a different cut-off value
of PSA bounce are expected in the near future.
Conclusions
There is no significant difference in the prevalence of
PSA bounce between groups treated with LDR-
brachytherapy alone and those treated with LDR-
brachytherapy in combination with EBRT, regardlessof neoadjuvant ADT. In hormone-naïve patients trea-
ted with LDR-brachytherapy alone, %UD90 was the
most significant predictor of PSA bounce.
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